Medical condition
Type 1 Diabetes
Type 1 Diabetes is a medical condition tracked by NovaPharmaNews across 3 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- dapagliflozin (FORXIGA) Alimentary tract and metabolism (A10)
- sotagliflozin (ZYNQUISTA) Alimentary tract and metabolism (A10)
- teplizumab (TEIZEILD) Alimentary tract and metabolism (A10)
Latest Type 1 Diabetes news
Tracking Cellular Disruptions in Type 1 Diabetes: Insights for Pharma
This article explores recent findings on cellular disruptions linked to type 1 diabetes and their implications for pharmaceutical development and investment.
Sanofi's Tzield Approved by FDA for Children as Young as 1 Year to Delay Type 1 Diabetes Progression
FDA expands Tzield approval for children aged 1+ with stage 2 type 1 diabetes, marking first disease-modifying therapy to delay insulin dependence.
FDA Approves Sanofi's Tzield for Children Age 1+ to Delay Type 1 Diabetes Onset
Sanofi's Tzield becomes first disease-modifying therapy approved for children as young as one year old to delay insulin-dependent Type 1 diabetes progression.